Cetuximab promotes epithelial to mesenchymal transition and cancer associated fibroblasts in patients with head and neck cancer

Oncotarget

Volumn 6, Issue 33, 2015, Pages 34288-34299

  Schmitz, Sandra ^a   Bindea, Gabriela ^b,c,d   Albu, Roxana Irina ^a   Mlecnik, Bernhard ^b,c,d   Machiels, Jean Pascal ^a  

^a CLINIQUES UNIVERSITAIRES SAINT LUC   (Belgium)

^b INSERM   (France)

^c UNIVERSITÉ PARIS DESCARTES   (France)

^d CENTRE DE RECHERCHE DES CORDELIERS   (France)

Author keywords

Anti EGFR therapy; Cancer associated fibroblasts; Epithelial mesenchymal transition; Head and neck cancer; Pharmacodynamic

Indexed keywords

CETUXIMAB; NOTCH RECEPTOR; WNT PROTEIN; ANTINEOPLASTIC AGENT; TRANSCRIPTOME;

ANTINEOPLASTIC ACTIVITY; ARTICLE; ASPN GENE; CANCER ASSOCIATED FIBROBLAST; CANCER CELL; CLINICAL ARTICLE; CONTROLLED STUDY; CXCL12 GENE; DRUG RESISTANCE; EPITHELIAL MESENCHYMAL TRANSITION; FAP GENE; FIBROBLAST; GENE; GENE EXPRESSION PROFILING; GENE OVEREXPRESSION; HEAD AND NECK SQUAMOUS CELL CARCINOMA; HUMAN; HUMAN TISSUE; LEF1 GENE; OLFM1 GENE; OLFML3 GENE; TUMOR GROWTH; TWIST1 GENE; UPREGULATION; ZEB1 GENE; ZNF521 GENE; CARCINOMA, SQUAMOUS CELL; CLINICAL TRIAL; DNA MICROARRAY; DRUG EFFECTS; FEMALE; HEAD AND NECK NEOPLASMS; IMMUNOHISTOCHEMISTRY; MALE; PATHOLOGY; REAL TIME POLYMERASE CHAIN REACTION;

ANTINEOPLASTIC AGENTS; CARCINOMA, SQUAMOUS CELL; CETUXIMAB; EPITHELIAL-MESENCHYMAL TRANSITION; FEMALE; FIBROBLASTS; HEAD AND NECK NEOPLASMS; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; REAL-TIME POLYMERASE CHAIN REACTION; TRANSCRIPTOME;

EID: 84946542657     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.5924     Document Type: Article

References (47)

1. Gregoire V, Lefebvre JL, Licitra L, Felip E and Group E-E-EGW. Squamous cell carcinoma of the head and neck: EHNS-ESMO-ESTRO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2010; 21 Suppl 5:v184-186.
2. Kalyankrishna S and Grandis JR. Epidermal growth factor receptor biology in head and neck cancer. J Clin Oncol. 2006; 24:2666-2672.
3. Ang KK, Berkey BA, Tu X, Zhang HZ, Katz R, Hammond EH, Fu KK and Milas L. Impact of epidermal growth factor receptor expression on survival and pattern of relapse in patients with advanced head and neck carcinoma. Cancer Res. 2002; 62:7350-7356.
4. Rubin Grandis J, Melhem MF, Gooding WE, Day R, Holst VA, Wagener MM, Drenning SD and Tweardy DJ. Levels of TGF-alpha and EGFR protein in head and neck squamous cell carcinoma and patient survival. J Natl Cancer Inst. 1998; 90:824-832.
5. Bentzen SM, Atasoy BM, Daley FM, Dische S, Richman PI, Saunders MI, Trott KR and Wilson GD. Epidermal growth factor receptor expression in pretreatment biopsies from head and neck squamous cell carcinoma as a predictive factor for a benefit from accelerated radiation therapy in a randomized controlled trial. J Clin Oncol. 2005; 23:5560-5567.
6. Bonner JA, Harari PM, Giralt J, Azarnia N, Shin DM, Cohen RB, Jones CU, Sur R, Raben D, Jassem J, Ove R, Kies MS, Baselga J, Youssoufian H, Amellal N, Rowinsky EK, et al. Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. N Engl J Med. 2006; 354:567-578.
7. Vermorken JB, Mesia R, Rivera F, Remenar E, Kawecki A, Rottey S, Erfan J, Zabolotnyy D, Kienzer HR, Cupissol D, Peyrade F, Benasso M, Vynnychenko I, De Raucourt D, Bokemeyer C, Schueler A, et al. Platinum-based chemotherapy plus cetuximab in head and neck cancer. N Engl J Med. 2008; 359:1116-1127.
8. Machiels JP, Subramanian S, Ruzsa A, Repassy G, Lifirenko I, Flygare A, Sorensen P, Nielsen T, Lisby S and Clement PM. Zalutumumab plus best supportive care versus best supportive care alone in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck after failure of platinum-based chemotherapy: an open-label, randomised phase 3 trial. Lancet Oncol. 2011; 12:333-343.
9. Karapetis CS, Khambata-Ford S, Jonker DJ, O'Callaghan CJ, Tu D, Tebbutt NC, Simes RJ, Chalchal H, Shapiro JD, Robitaille S, Price TJ, Shepherd L, Au HJ, Langer C, Moore MJ and Zalcberg JR. K-ras mutations and benefit from cetuximab in advanced colorectal cancer. N Engl J Med. 2008; 359:1757-1765.
10. Chung JH, Rho JK, Xu X, Lee JS, Yoon HI, Lee CT, Choi YJ, Kim HR, Kim CH and Lee JC. Clinical and molecular evidences of epithelial to mesenchymal transition in acquired resistance to EGFR-TKIs. Lung Cancer. 2011; 73:176-182.
11. Basu D, Bewley AF, Sperry SM, Montone KT, Gimotty PA, Rasanen K, Facompre ND, Weinstein GS, Nakagawa H, Diehl JA, Rustgi AK and Herlyn M. EGFR inhibition promotes an aggressive invasion pattern mediated by mesenchymal-like tumor cells within squamous cell carcinomas. Mol Cancer Ther. 2013; 12:2176-2186.
12. Johansson AC, Ansell A, Jerhammar F, Lindh MB, Grenman R, Munck-Wikland E, Ostman A and Roberg K. Cancer-associated fibroblasts induce matrix metalloproteinase-mediated cetuximab resistance in head and neck squamous cell carcinoma cells. Mol Cancer Res. 2012; 10:1158-1168.
13. Astekar M, Metgud R, Sharma A and Soni A. Hidden keys in stroma: Unlocking the tumor progression. J Oral Maxillofac Pathol. 2013; 17:82-88.
14. Chargari C, Clemenson C, Martins I, Perfettini JL and Deutsch E. Understanding the functions of tumor stroma in resistance to ionizing radiation: emerging targets for pharmacological modulation. Drug resistance updates: reviews and commentaries in antimicrobial and anticancer chemotherapy. 2013; 16:10-21.
15. Cukierman E and Bassi DE. The mesenchymal tumor microenvironment: a drug-resistant niche. Cell adhesion & migration. 2012; 6:285-296.
16. Schmitz S, Hamoir M, Reychler H, Magremanne M, Weynand B, Lhommel R, Hanin FX, Duprez T, Michoux N, Rommel D, Lonneux M, Cappoen N, Gillain A and Machiels JP. Tumour response and safety of cetuximab in a window pre-operative study in patients with squamous cell carcinoma of the head and neck. Ann Oncol. 2013; 24:2261-2266.
17. Bindea G, Mlecnik B, Hackl H, Charoentong P, Tosolini M, Kirilovsky A, Fridman WH, Pages F, Trajanoski Z and Galon J. ClueGO: a Cytoscape plug-in to decipher functionally grouped gene ontology and pathway annotation networks. Bioinformatics. 2009; 25:1091-1093.
18. Natarajan J, Chandrashekar C and Radhakrishnan R. Critical biomarkers of epithelial-mesenchymal transition in the head and neck cancers. J Cancer Res Ther. 2014; 10(3):512-518.
19. Scanlon CS, Van Tubergen EA, Inglehart RC and D'Silva NJ. Biomarkers of epithelial-mesenchymal transition in squamous cell carcinoma. J Dent Res. 2013; 92:114-121.
20. Bindea G, Galon J and Mlecnik B. CluePedia Cytoscape plugin: pathway insights using integrated experimental and in silico data. Bioinformatics. 2013; 29:661-663.
21. Hakelius M, Saiepour D, Goransson H, Rubin K, Gerdin B and Nowinski D. Differential Gene Regulation in Fibroblasts in Co-culture with Keratinocytes and Head and Neck SCC Cells. Anticancer Res. 2015; 35:3253-3265.
22. Berdiel-Acer M, Sanz-Pamplona R, Calon A, Cuadras D, Berenguer A, Sanjuan X, Paules MJ, Salazar R, Moreno V, Batlle E, Villanueva A and Mollevi DG. Differences between CAFs and their paired NCF from adjacent colonic mucosa reveal functional heterogeneity of CAFs, providing prognostic information. Mol Oncol. 2014; 8:1290-1305.
23. Farmer P, Bonnefoi H, Anderle P, Cameron D, Wirapati P, Becette V, Andre S, Piccart M, Campone M, Brain E, Macgrogan G, Petit T, Jassem J, Bibeau F, Blot E, Bogaerts J, et al. A stroma-related gene signature predicts resistance to neoadjuvant chemotherapy in breast cancer. Nat Med. 2009; 15:68-74.
24. Walter V, Yin X, Wilkerson MD, Cabanski CR, Zhao N, Du Y, Ang MK, Hayward MC, Salazar AH, Hoadley KA, Fritchie K, Sailey CJ, Weissler MC, Shockley WW, Zanation AM, Hackman T, et al. Molecular subtypes in head and neck cancer exhibit distinct patterns of chromosomal gain and loss of canonical cancer genes. PLoS One. 2013; 8:e56823.
25. Tralhao JG, Schaefer L, Micegova M, Evaristo C, Schonherr E, Kayal S, Veiga-Fernandes H, Danel C, Iozzo RV, Kresse H and Lemarchand P. In vivo selective and distant killing of cancer cells using adenovirus-mediated decorin gene transfer. FASEB J. 2003; 17:464-466.
26. Goldoni S, Seidler DG, Heath J, Fassan M, Baffa R, Thakur ML, Owens RT, McQuillan DJ and Iozzo RV. An antimetastatic role for decorin in breast cancer. Am J Pathol. 2008; 173:844-855.
27. Csordas G, Santra M, Reed CC, Eichstetter I, McQuillan DJ, Gross D, Nugent MA, Hajnoczky G and Iozzo RV. Sustained down-regulation of the epidermal growth factor receptor by decorin. A mechanism for controlling tumor growth in vivo. J Biol Chem. 2000; 275:32879-32887.
28. Iozzo RV, Moscatello DK, McQuillan DJ and Eichstetter I. Decorin is a biological ligand for the epidermal growth factor receptor. J Biol Chem. 1999; 274:4489-4492.
29. Santra M, Eichstetter I and Iozzo RV. An anti-oncogenic role for decorin. Down-regulation of ErbB2 leads to growth suppression and cytodifferentiation of mammary carcinoma cells. J Biol Chem. 2000; 275:35153-35161.
30. Goldoni S, Humphries A, Nystrom A, Sattar S, Owens RT, McQuillan DJ, Ireton K and Iozzo RV. Decorin is a novel antagonistic ligand of the Met receptor. J Cell Biol. 2009; 185:743-754.
31. Schonherr E, Sunderkotter C, Iozzo RV and Schaefer L. Decorin, a novel player in the insulin-like growth factor system. J Biol Chem. 2005; 280:15767-15772.
32. Zhang Y, Wang Y, Du Z, Wang Q, Wu M, Wang X, Wang L, Cao L, Hamid AS and Zhang G. Recombinant human decorin suppresses liver HepG2 carcinoma cells by p21 upregulation. Onco Targets Ther. 2012; 5:143-152.
33. Sullivan MM, Barker TH, Funk SE, Karchin A, Seo NS, Hook M, Sanders J, Starcher B, Wight TN, Puolakkainen P and Sage EH. Matricellular hevin regulates decorin production and collagen assembly. J Biol Chem. 2006; 281:27621-27632.
34. Orr B, Riddick AC, Stewart GD, Anderson RA, Franco OE, Hayward SW and Thomson AA. Identification of stromally expressed molecules in the prostate by tag-profiling of cancer-associated fibroblasts, normal fibroblasts and fetal prostate. Oncogene. 2012; 31:1130-1142.
35. Torres S, Bartolome RA, Mendes M, Barderas R, Fernandez-Acenero MJ, Pelaez-Garcia A, Pena C, LopezLucendo M, Villar-Vazquez R, de Herreros AG, Bonilla F and Casal JI. Proteome profiling of cancer-associated fibroblasts identifies novel proinflammatory signatures and prognostic markers for colorectal cancer. Clin Cancer Res. 2013; 19:6006-6019.
36. Miljkovic-Licina M, Hammel P, Garrido-Urbani S, Lee BP, Meguenani M, Chaabane C, Bochaton-Piallat ML and Imhof BA. Targeting olfactomedin-like 3 inhibits tumor growth by impairing angiogenesis and pericyte coverage. Mol Cancer Ther. 2012; 11:2588-2599.
37. Orimo A and Weinberg RA. Stromal fibroblasts in cancer: a novel tumor-promoting cell type. Cell cycle. 2006; 5:1597-1601.
38. Teicher BA and Fricker SP. CXCL12 (SDF-1)/CXCR4 pathway in cancer. Clin Cancer Res. 2010; 16:2927-2931.
39. Faber A, Goessler UR, Hoermann K, Schultz JD, Umbreit C and Stern-Straeter J. SDF-1-CXCR4 axis: cell trafficking in the cancer stem cell niche of head and neck squamous cell carcinoma. Oncol Rep. 2013; 29:2325-2331.
40. Fusi A, Liu Z, Kummerlen V, Nonnemacher A, Jeske J and Keilholz U. Expression of chemokine receptors on circulating tumor cells in patients with solid tumors. J Transl Med. 2012; 10:52.
41. Domanska UM, Timmer-Bosscha H, Nagengast WB, Oude Munnink TH, Kruizinga RC, Ananias HJ, Kliphuis NM, Huls G, De Vries EG, de Jong IJ and Walenkamp AM. CXCR4 inhibition with AMD3100 sensitizes prostate cancer to docetaxel chemotherapy. Neoplasia. 2012; 14:709-718.
42. Petz M, Them NC, Huber H and Mikulits W. PDGF enhances IRES-mediated translation of Laminin B1 by cytoplasmic accumulation of La during epithelial to mesenchymal transition. Nucleic Acids Res. 2012; 40:9738-9749.
43. Keysar SB, Le PN, Anderson RT, Morton JJ, Bowles DW, Paylor JJ, Vogler BW, Thorburn J, Fernandez P, Glogowska MJ, Takimoto SM, Sehrt DB, Gan GN, Eagles-Soukup JR, Serracino H, Hirsch FR, et al. Hedgehog signaling alters reliance on EGF receptor signaling and mediates anti-EGFR therapeutic resistance in head and neck cancer. Cancer Res. 2013; 73:3381-3392.
44. Zhang X, Liu G, Kang Y, Dong Z, Qian Q and Ma X. N-cadherin expression is associated with acquisition of EMT phenotype and with enhanced invasion in erlotinibresistant lung cancer cell lines. PLoS One. 2013; 8:e57692.
45. Casas-Selves M, Kim J, Zhang Z, Helfrich BA, Gao D, Porter CC, Scarborough HA, Bunn PA, Jr., Chan DC, Tan AC and DeGregori J. Tankyrase and the canonical Wnt pathway protect lung cancer cells from EGFR inhibition. Cancer Res. 2012; 72:4154-4164.
46. Stewart DJ. Wnt signaling pathway in non-small cell lung cancer. J Natl Cancer Inst. 2014; 106:djt356.
47. Gujral TS, Chan M, Peshkin L, Sorger PK, Kirschner MW and MacBeath G. A noncanonical frizzled2 pathway regulates epithelial-mesenchymal transition and metastasis. Cell. 2014; 159:844-856.